Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
As of today, Moderna(MRNA) shares are valued at $49.92. The company's market cap stands at 19.49B, with a P/E ratio of -6.87.
On 2026-02-21, Moderna(MRNA) stock traded between a low of $48.30 and a high of $50.47. Shares are currently priced at $49.92, which is +3.4% above the low and -1.1% below the high.
Moderna(MRNA) shares are trading with a volume of 9.03M, against a daily average of 10.95M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
MRNA News
Key Points Philippe Laffont bought shares of CoreWeave in the first quarter of last year and recently closed that position. The investor favors tech stocks an...
Moderna (MRNA) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in...
BioNTech SE (NASDAQ:BNTX) has filed a patent infringement lawsuit against Moderna Inc. (NASDAQ:MRNA) , alleging that Moderna's next-generation COVID-19 vaccine,...
Analyst ratings
70%
of 27 ratingsMore MRNA News
Advertisement Why Moderna (MRNA) is on investors’ radar today Moderna (MRNA) has drawn fresh attention after recent share price moves, with the stock showing...
Analyst Alec Stranahan from Bank of America Securities reiterated a Sell rating on Moderna and increased the price target to $31.00 from $27.00. President's Day...
So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy? Vaccine specialist Moderna (MRNA +5.37%) stock soared...
The stock’s movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license application for mRNA-1010 will proceed...
RBC Capital said the FDA’s decision to reverse course and review Moderna’s (MRNA) flu vaccine application comes with limited detail, but the firm’s read is that...
Moderna (MRNA) stock rose about 7% on Wednesday morning after the Food and Drug Administration reversed its earlier stance and agreed to review the company’s ap...
In February 2026, Moderna reported full-year 2025 revenue of US$1.94 billion and a net loss of US$2.82 billion, while the FDA’s vaccines center issued a refusal...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.